Impact of Protein Content of Ultraprocessed Foods on the Regulation of Energy Balance

Sponsor
University of Kiel (Other)
Overall Status
Recruiting
CT.gov ID
NCT05337007
Collaborator
(none)
24
1
2
11.5
2.1

Study Details

Study Description

Brief Summary

Aim of the study is to investigate the effects of high-protein, ultraprocessed foods on the regulation of energy balance in a metabolic chamber. The primary outcome parameter of the study is the energy balance (ad libitum energy intake and energy expenditure).

Condition or Disease Intervention/Treatment Phase
  • Other: high protein diet
  • Other: moderate protein diet
N/A

Detailed Description

Each of the two study weeks starts with a 3-day run-in period with controlled diet at home, following 48 hours in a metabolic chamber. On the day the participants leave the metabolic chamber, they keep a food record over the rest of the day at home.

  1. week: meals containing 30 % protein (80 % ultraprocessed high-protein foods), physical activity level (PAL) 1.45, 2 intervention days in the metabolic chamber: ad libitum energy intake

  2. week: meals containing 13 % protein (80 % ultraprocessed foods with moderate protein content), physical activity level (PAL) 1.45, 2 intervention days in the metabolic chamber: ad libitum energy intake

Study Design

Study Type:
Interventional
Anticipated Enrollment :
24 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Intervention Model Description:
all subjects are undergoing each interventionall subjects are undergoing each intervention
Masking:
Single (Participant)
Primary Purpose:
Basic Science
Official Title:
Impact of Protein Content of Ultraprocessed Foods on the Regulation of Energy Balance (ad Libitum Energy Intake and Energy Expenditure)
Actual Study Start Date :
May 4, 2022
Anticipated Primary Completion Date :
Apr 18, 2023
Anticipated Study Completion Date :
Apr 18, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: dietary intervention, high protein diet

commercially available high protein ultraprocessed food items (30% protein content), cross-over design, all subjects receive all interventions

Other: high protein diet
48 hours intervention with a 'high protein' ad libitum diet (30 % protein; 80 % commercially available ultraprocessed foods) to measure energy balance in a metabolic chamber at physical activity level of 1.45

Active Comparator: dietary intervention, moderate protein diet

commercially available moderate protein ultraprocessed food items (13% protein content), cross-over design, all subjects receive all interventions

Other: moderate protein diet
48 hours intervention with a 'moderate protein' ad libitum diet (13 % protein; 80 % commercially available ultraprocessed foods) to measure energy balance in a metabolic chamber at physical activity level of 1.45

Outcome Measures

Primary Outcome Measures

  1. ad libitum energy intake [24 hours]

    ad libitum energy intake (kcal/day) of the foods consumed (breakfast, lunch, dinner, snacks)

  2. energy expenditure [24 hours]

    measured with indirect calorimetry in a metabolic chamber (kcal/day)

Secondary Outcome Measures

  1. macronutrient oxidation [24 hours]

    measured with indirect calorimetry in a metabolic chamber (respiratory quotient, RQ)

  2. glycemia - glucose AUC [24 hours]

    glucose AUC from continuous glucose monitoring data (mg/dL x 24 hours)

  3. eating rate [3 x 30 per 24 hours (during main meals)]

    time to finish the meals (breakfast, lunch, dinner), (kcal/min; g/min)

  4. oral processing behaviour (chewing) [3 x 30 per 24 hours (during main meals)]

    chews per bite, bite size, oral exposure per bite

  5. gastric emptying [5 hours after breakfast on first day of each intervention; intervals 15 min]

    measured with 13C-octanoic acid breath test

  6. appetite regulating hormone - ghrelin [5 hours after breakfast on second day of each intervention; intervals 30 min]

    Ghrelin concentration in plasma (15 hours AUC; pg/mL)

  7. appetite regulating hormone - GLP-1 [5 hours after breakfast on second day of each intervention; intervals 30 min]

    Glucose Like Peptide-1 concentration in plasma (15 hours AUC; pg/mL)

  8. appetite regulating hormone - PYY [5 hours after breakfast on second day of each intervention; intervals 30 min]

    Peptide YY concentration in plasma (15 hours AUC; pg/mL)

  9. appetite control - subjective feelings of hunger [5 hours after breakfast on first day of each intervention; intervals 30 min]

    measured with visual analogue scales (5 hours AUC; mm x 5 hours). The scale consists of a 10 cm vertical line anchored with "not hungry at all" at the left side and with "extremely hungry" at the right side.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 35 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • healthy

  • BMI 19-29 kg/m2

  • low-medium habitual physical activity

  • women with regular menstrual cycle (during intervention in follicular phase)

Exclusion Criteria:
  • smoking

  • chronic illnesses (e.g. renal dysfunction)

  • regular intake of medication

  • food allergies / intolerances

  • vegans and vegetarians

  • regular high physical activity (exercise >1 hour/d)

  • current weight loss diet / weight loss of >5 kg in the last 3 months

  • pregnant / lactating women

  • persons incapable of giving informed legal consent

  • restraint eaters (according to the German version of the 'Three-Factor-Eating-Questionnaire', Stunkard und Messick (1985))

Contacts and Locations

Locations

Site City State Country Postal Code
1 Institute of Human Nutrition Kiel Germany 24105

Sponsors and Collaborators

  • University of Kiel

Investigators

  • Principal Investigator: Anja Bosy-Westphal, PhD, MD, Institute of Human Nutrition, Kiel University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Prof. Dr. Dr. Anja Bosy-Westphal, Prof. Dr. Dr. Anja Bosy-Westphal, University of Kiel
ClinicalTrials.gov Identifier:
NCT05337007
Other Study ID Numbers:
  • ABW-2022-HP
First Posted:
Apr 20, 2022
Last Update Posted:
May 4, 2022
Last Verified:
May 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Prof. Dr. Dr. Anja Bosy-Westphal, Prof. Dr. Dr. Anja Bosy-Westphal, University of Kiel

Study Results

No Results Posted as of May 4, 2022